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Summary The aim of this study was to evaluate the efficacy of high-dose paclitaxel in patients with previously untreated stage IV epithelial
ovarian cancer. Paclitaxel was administered intravenously over 3 h at a dose of 225 mg m-2 on a 21-day cycle for six courses. Thirty-six
patients were entered into this study; all 36 were assessed for toxicity and 33 patients were evaluable for response. One patient had a
complete response and 12 patients had partial responses (overall response rate 39.4%, 95% Cl 23-58%). The overall median duration of
response was 9 months (range 3.5-23+ months). The response rate to carboplatin following failure of paclitaxel within 1 year of stopping
therapy was 57% (four out of seven patients). The median survival of patients was 17.2 months. The main toxicity encountered was
neutropenia which was WHO grade 3 in 11 patients (31%) and WHO grade 4 in seven patients (19%). Granulocyte colony-stimulating factor
(GCSF) was not given to any patient during the study. Other toxicities were: grade 3/4 infection (11%) and nausea and vomiting (11%); grade
3 bone pain (22%), fatigue (14%), diarrhoea (3%), myalgia/arthralgia (3%) and dry eyes (3%). Transient peripheral neuropathy occurred in 16
patients (44%), and alopecia was encountered in most patients (grade 2/3, 78%). Paclitaxel given at 225 mg m-2 to patients with stage IV
epithelial ovarian cancer is active, well tolerated and does not require GCSF support.
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Stage IV epithelial ovarian cancer is defined by the International
Federation of Gynaecology and Obstetrics (FIGO) as a tumour
involving one orboth ovaries with distant metastases. The presence
of a pleural effusion is only regarded as indicating this stage ofthe
disease ifthe fluid is cytologically positive for malignant epithelial
cells and, similarly, only parenchymal hepatic metastases, as
opposed to surface liver tumours, place the patient into the stage IV
category (FIGO, 1987). The prognosis of patients with stage IV
epithelial ovarian cancer is very poor despite advances in therapy
over the last 20 years; median survivals of 16 months are reported
with 5-14% ofpatients surviving 5 years and < 5% ofpatients alive
at 10 years (Pettersson et al, 1988; Neijt et al, 1991). Paclitaxel
is active in pretreated patients with relapsed epithelial ovarian
cancer and those with disease resistant to platinum compounds.
Cumulative overall response rates range from 15% to 24% when
the drug is given at 135 and 175 mg m-2 respectively (Markman et
al, 1993; Trimble et al, 1993; Aravantinos et al, 1994; Athanassiou
et al, 1994; Eisenhauer et al, 1994; Seewaldt et al, 1994; Thigpen et
al, 1994; Uziely et al, 1994; Gore et al, 1995a). There are data to
suggest that there is a dose - response relationship with this drug
and, for patients with relapsed or refractory disease who received
250 mg m-2, response rates of 20-71% have been reported (Einzig
et al, 1992; Kavanagh et al, 1993; Kohn et al, 1994).
There are no data on the activity ofpaclitaxel when it is given as
a single agent to patients with previously untreated advanced
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epithelial ovarian cancer and, because patients with stage IV
disease have such a poor prognosis, they are candidates for such
novel treatments, which have shown promising results in the
relapse setting. We argued that ifsingle-agentpaclitaxel were tobe
tested in chemonaive stage IV patients it would be logical to use it
in high dosage. In this way, it may be possible to improve on the
results of the platinum-based strategies that were ongoing at the
time this study started. We present here the results ofthis phase II
trial of high-dose single-agent paclitaxel in previously untreated
patients with epithelial ovarian cancer.
MATERIALS AND METHODS
Patients
The study was performed as a collaboration between two London-
based trial groups, the London Gynaecological Oncology Group
(Royal Marsden, Royal London, Middlesex and Addenbrooke's
Hospitals) and the North Thames Gynaecological Oncology
Group (Charing Cross and Mount Vernon Hospitals). The study
opened to accrual in March 1993 and closed in October 1994. All
patients presenting with stage IV epithelial ovarian cancer were
considered for entry into the trial. Patients had to have histologi-
cally proven disease, tumour that was measurable either uni- or
bidimensionally, no previous chemotherapy or radiotherapy, and
treatment had to commence within 8 weeks of laparotomy.
Patients had to be aged 18-75 years, have a performance status of
0-1 (ECOG), a life expectancy of greater than 12 weeks and
adequate haematological, renal and hepatic function (absolute
neutrophil count > 1.5 x 1091-',platelet count 2 100 x 109 1-', total
bilirubin < 1.25 x upper limit of normal unless due to metastases,
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Table 1 Patient characteristics
Total number of patients entered
Stage IlIl
Stage IV
Median age (range) (years)
Surgery
TAH, BSO + omentectomy
Biopsy only
Residual disease
< 2 cm
2-5 cm
6-10 cm
> 10cm
Stage IV - defining sites
Liver + lung + distant lymph nodes
Liver + distant lymph nodes
Lung + distant lymph nodes
Distant lymph nodes only
Other (e.g. skin)
Inguinal nodes (stage ll)
36
2
34
57 (20-73)
29
7
4
10
13
9
13
10
6
3
2
2
creatinine < 1.25 x upper limit of normal). Patient consent was
obtained according to the requirements of the local institution's
ethics committee. Patients with a past history of malignancy,
except for non-melanoma skin cancer or curatively treated carci-
noma in situ ofthe uterine cervix, were excluded from the study, as
were patients with borderline ovarian tumours and those with a
diagnosis of intra-abdominal adenocarcinoma of unknown origin.
Patients were also excluded if they had serious cardiac disease,
complete bowel obstruction, pre-existing motor or sensory
neuropathy > WHO grade 1, active infections or any other serious
underlying medical condition.
Treatment
Paclitaxel was administered intravenously over 3 h in 500 ml of5%
dextrose at a dose of 225 mg m-2 in glass containers using polyeth-
ylene-lined nitroglycerine tubing and in-line filtration on a 21-day
cycle. In order to reduce the incidence ofhypersensitivity reactions,
patients were premedicated with 20 mg ofdexamethasone orally 12
and 6 h before chemotherapy and chlorpheniramine (10 mg) and
cimetidine (300 mg) were both given intravenously 30 min before
chemotherapy. The intended number of courses was six but this
could be extended at the investigators discretion for patients who
showed evidence of continuing response. Dose reductions were
required for both haematological and non-haematological toxicity
and were as follows: dose reduction level 1, 200 mg m-2; level 2,
175 mg m-2; level 3, 135 mg m-2; level 4, 110 mg m-2; level 5, 90
mg m-2. A neutrophil count of< 0.5 x 109 1-' and/orplatelet count <
50 x 1091-1 present for . 7 days resulted in a decrease of one dose
level. Febrile episodes associated with a neutrophil count < 0.5 x
109 1-' for . 7 days or episodes of severe bleeding resulted in a
reduction oftwo dose levels. Courses oftreatment were only given
if the neutrophil count was > 1.5 x 109 1-' and the platelet count >
100 x 1091-'. If haematological recovery was not achieved by day
42 of a cycle, the patient was removed from the study. For patients
with grade 2 mucositis or peripheral neuropathy, paclitaxel was
reduced by one dose level but if . WHO grade 3 peripheral
neuropathy or other major organ toxicities occurred then paclitaxel
was stopped and the patient removed from the study.
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Figure 1 Progression-free survival of all 36 patients with stage IV epithelial
ovarian cancer treated with paclitaxel (225 mg m-2)
Patient assessment
Patients were assessed for response after each course of treatment
by physical examination and, after every third course of therapy
and at the time of discontinuing treatment, by an appropriate
imaging technique, e.g. radiography, ultrasonography, computer-
ized axial tomography or magnetic resonance imaging. Serum
CA125 was not used for response assessment. Response was
defined according to standard UICC criteria i.e. complete
response, complete disappearance of all disease for at least 4
weeks; partial response, a decrease by 50% ofthe sum ofthe prod-
ucts of two perpendicular diameters of all measured lesions
without the appearance of any new lesions for at least 4 weeks;
progressive disease, development of new lesions or an increase of
any measured lesion by > 25% of the sum of the products of two
perpendicular diameters; stable disease, no change in measurable
lesions or changes that did not fulfil the criteria of either partial
response or progressive disease for at least 8 weeks. There was no
independent review of the images used to assess response, but
patient records were carefully examined and the reports on which
responses were based were scrutinized. In particular we checked
that responses were confirmed by follow-up investigations.
Response duration was measured from the start oftreatment to the
date that progressive disease was diagnosed for partial responders
and, for complete responders, the duration ofresponse lasted from
the date the complete response was first recorded to the date of
relapse. Overall survival was calculated from the date of the first
treatment cycle.
Objective toxicities were assessed before each course (full
blood count, serum biochemistry and liver function tests), at which
time patients were physically examined and questioned about
subjective toxicities, which were graded according to standard
WHO criteria. There were additional weekly assessments of
myelosuppression by full blood counts.
RESULTS
Patient characteristics
Thirty-six patients entered the study and their characteristics are
shown in Table 1. On review, two patients did not have stage IV
disease but did have advanced epithelial ovarian cancer (stage III)
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Figure 2 Survival of all 36 patients with stage IV epithelial ovarian cancer
treated with paclitaxe (225 mg m-2)
Table 2 Non-haematological toxicities in all 36 patients
WHO grade
0 1 2 3 4
Nausea/vomiting 15 8 9 3 1
Infection 20 4 8 3 1
Alopecia 5 3 6 22 0
Bone pain 19 4 5 8 0
Fatigue 3 10 18 5 0
Diarrhoea 22 7 6 1 0
Myalgia/arthralgia 28 2 5 1 0
Dry eyes 31 2 2 1 0
Ototoxicity 34 1 0 1 0
Neurotoxicity 9 11 16 0 0
Mucositis 23 7 6 0 0
Oedema 28 3 5 0 0
Data presented as worst grade per patient.
and were therefore kept in the analysis. The median age of the
patients was 57 years (range 20-73). Twenty-nine patients had a
total abdominal hysterectomy (TAH), bilateral salpingo-oophorec-
tomy (BSO) and/or an omentectomy and seven patients had a
biopsy only. Disease sites were as follows: parenchymal liver and
pulmonary metastases and/or distant lymph nodes, 13 patients
(36%); parenchymal liver metastases and/or distant lymph nodes,
ten patients (28%); pulmonary metastases and/or distant lymph
nodes, six patients (17%); distant lymph nodes only, three patients
(8%); other metastatic sites (e.g. skin), two patients (5.5%);
inguinal lymph nodes only, two patients (5.5%) - these were the
two patients who were wrongly categorized as having stage IV
disease. The median number of sites of disease was five. The
largest measureable lesion was <2 cm in four patients (11%), 2-5
cm in ten patients (28%), 6-10 cm in 13 patients (36%) and >10
cm in nine patients (25%).
Response
Three patients were not considered evaluable for response: two
patients were ineligible for the study because on review they
were found to have synchronous primary lesions (caecum and
endometrium); one patient developed severe uncontrollable
hypertension during her first infusion of paclitaxel, and treatment
had to be abandoned. Thirty-three patients were therefore evalu-
able for response: one patient had a complete response, 12 patients
had a partial response (overall response rate 39.4%, 95% CI
23-58%) and seven patients had stable disease. The duration ofthe
complete response was 8.5 months; 8 of the 12 partial responders
have relapsed at a median of 7 months (range 3.5-12 months), but
four patients remain in a good partial remission at 6+, 10+, 13+
and 23+ months. The overall median duration of response was
therefore 9 months (range 3.5-23+ months, Figure 1). The median
survival was 17.2 months, with 63% of patients surviving 1 year
(Figure 2).
Seven patients received subsequent carboplatin for relapsed or
refractory disease. The results were as follows: three patients
relapsed within 4 months of stopping paclitaxel, one patient
responded; two patients relapsed between 4 and 12 months ofstop-
ping paclitaxel, one patient responded; two patients had disease
primarily resistant to paclitaxel and both responded. The overall
response rate to carboplatin following failure ofpaclitaxel within 1
year of stopping therapy was therefore 57%
patients).
(four out of seven
Toxicity
All 36 patients were evaluable for toxicity. The main toxicity
encountered in this study was neutropenia, with 11 patients (31%)
and seven patients (19%) experiencing WHO grade 3 and 4 toxi-
city, respectively, although 11 patients (31%) had no fall in
neutrophil count at any time. Anaemia (Hb < 11.0 g 1-'), was rarely
encountered; four(11%) and three (8%) patients had WHO grade 1
and 2 anaemia, respectively, and no thrombocytopenia was seen.
Non-haematological toxicities are shown in Table 2 WHO grade
4 toxicities were very rarely seen; grade 3/4 nausea/vomiting and
infections occurred in 11% of patients each. Most patients (78%)
experienced noticable alopecia (grade 2/3). Other significant toxici-
ties (grade 3) included: bone pain (22%), fatigue (14%), diarrhoea
(3%), myalgia/arthralgia (3%), dry eyes (3%) and ototoxicity (3%).
Peripheral neuropathy (grade 2) occurred in44% ofpatients but was
not permanent and reversed. Oedema and mucositis were infrequent
(22 and 36% respectively) andmild(grade 1/2).As describedabove,
11% ofpatients developed 3/4 neutropenia (four patients), but only
one patient who died of peritonitis (see below) was classified as
having grade 4 infection; the other three patients who developed
grade 3 infections did so without associated neutropenia. Their
infections were short-lived and did not require intravenous antibi-
otics, and therefore the dose of paclitaxel they received on subse-
quent courses was not reduced.
The median number of courses received was 5.5 (range 1-10).
Ninepatients haddosereductions,allbecauseofneurotoxicity. Three
of the patients had three dose reductions and one patient had two
reductions. Eight courses of treatment were delayed, six of which
were for administrative or social reasons e.g. national holiday, bed
shortages, etc, one because ofan episode ofbleeding per rectum and
onefollowing debulking interval surgery. Fourpatients stopped treat-
ment early because of toxicity, the reason for each patient being as
follows: bonepain andperipheral neuropathy,depression andperiph-
eral neuropathy, brachycardia, hypertension during the infusion of
her first cycle ofchemotherapy (described above). Early deaths were
defined as those occurring before cycle 2 and there were four: two
becauseofprogressive disease,one because ofapulmonaryembolus,
and one patientdied ofperitonitis secondary to intestinal obstruction.
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The median overall dose intensity in this study was 75 mg m-2
per week (range 57.8-76.6 mg m-2), and this was the target dose
intensity. The median relative dose intensity for this study was
therefore 1 (0.77-1.02). The relative dose intensity for the treat-
ment expressed as a percentage for all 36 patients who entered the
study was as follows: less than 80%, one patient (3%); 80-90%,
four patients (11%); greater than 90%, 31 patients (86%).
DISCUSSION
Paclitaxel has been shown to be active in platinum-refractory
disease and in those patients who have relapsed early after plat-
inum-based therapy. There is a suggestion of a dose response to
paclitaxel in relapsed or refractory disease in that 19% ofpatients
responded to 135 mg m-2 (Markman et al, 1993; Trimble et al,
1993; Aravantinos et al, 1994; Eisenhauer et al, 1994; Seewaldt et
al, 1994; Uziely et al, 1994; Gore et al, 1995a) and 40% patients
responded to 225 mg m-2 (Einzig et al, 1992; Kavanagh et al,
1993; Kohn et al, 1994); although a randomized study comparing
135 mg m-2 and 175 mg m-2, in this situation, failed to show any
statistically significant difference (Eisenhauer et al, 1994).
Recently, the Gynaecological Oncology Group presented the
results of a randomized trial comparing paclitaxel and cisplatin
against standard therapy, cisplatin plus cyclophosphamide
(Protocol No. 111; McGuire et al, 1996). There was a clear overall
survival difference in favour of the paclitaxel combination, and it
is now the view of many investigators that paclitaxel is an essen-
tial part ofany first-line treatment. However, there were no data on
the use of paclitaxel as a single agent in previously untreated
patients before our commencing this study, which presents the
results of a relatively high dose of paclitaxel being used in this
context. The overall response rate of 39.4%, in our study, is
perhaps slightly lower than might be expected in view of the data
from GOG Protocol No. 111, and this suggests that there may be
some additive effects between paclitaxel and cisplatin. Recent
studies have shown at least some interaction between paclitaxel
and platinum compounds, with paclitaxel - carboplatin combina-
tions appearing to result in a reduction of carboplatin-induced
thrombocytopenia rather than the increase that would normally be
predicted (Ozols et al, 1993; Belani et al, 1994; ten Bokkel
Huinink et al, 1994).
Although we have been a little disappointed with the overall
response rate in this study, two findings suggest that single-agent
high-dose paclitaxel may have a role. Firstly, there was minimal
serious toxicity associated with the treatment and, indeed, pacli-
taxel was well tolerated in our patient population who have an
extremely poor prognosis. There were early deaths but none of
these appeared to be drug-related and all could be explained by the
advanced nature ofthe disease in our patient group. It is ofinterest
that we could deliver 225 mg m-2 of paclitaxel without any GCSF
support or excessive neurotoxicity and at the intended dose inten-
sity. Secondly, the duration of response to paclitaxel in this study
was very encouraging with a median of9 months (range 3.5-23+).
This compares very favourably with the 4.5-9.8 months range of
medians ofduration ofresponse reported for studies ofsingle-agent
paclitaxel in previously treated patients with relapsed/refractory
epithelial ovarian cancer (Trimble et al, 1993; Athanassiou et al,
1994; Eisenhauer et al, 1994; Thigpen et al, 1994; Uziely et al,
1994; Gore et al 1995b).
In single-agent studies such as this, there is always the possi-
bility that patient selection may bias the results, particularly in
terms of response rates, toxicity and survival. An important inde-
pendent prognostic factor in some, although not all, studies of
patients with advanced epithelial ovarian cancer is performance
status. Our patients were selected on their good performance status
(0-1), and this may have resulted in a bias in this study potentially
exaggerating the benefit oftreatment (Alberts et al, 1993; Hogberg
et al, 1993; Perren et al, 1993; McGuire et al, 1995). The reasons
for us confining this investigation to patients with a good perfor-
mance status were that, at the time we commenced the study, there
were still relatively little data on the precise toxicity profile associ-
ated with this dose of paclitaxel, particularly when given without
GCSF support. We therefore elected to be cautious with regard to
potential toxicity in this essentially palliative setting. There is a
possible negative bias in our study, however, in that only patients
with measurable disease were entered and the presence of macro-
scopic residual disease before commencing chemotherapy is a
well-accepted prognostic factor in patients with advanced ovarian
cancer. The reason for only entering patients with measurable
disease was that we wanted to have an indication ofthe activity of
single-agent paclitaxel in terms of response rates in previously
untreated patients. As a consequence, we have only studied
patients who might be described as having relatively bulky
disease. Our population may therefore not be representative, as
many patients who have minimal residual disease are categorized
as stage IV because ofa cytologically positive pleural effusion, for
example.
Our data also shows that there appears to be a degree of non-
cross-resistance between paclitaxel and carboplatin. We have
already shown that 26.7% patients with truly carboplatin-refrac-
tory disease can respond to doses of > 175 mg m-2 of paclitaxel,
and we have now found that two out of two patients with pacli-
taxel-refractory disease responded to carboplatin (Gore et al
1995b). These data suggest that it is logical to combine paclitaxel
with platinum compounds. Patients with stage IV epithelial
ovarian cancer have a very poor prognosis and treatment can be
regarded as being palliative. In this study, we have been able to
demonstrate the efficacy of single-agent paclitaxel in advanced
epithelial ovarian cancer and to show that the results, in terms of
the therapeutic ratio for this patient group, are good in view ofthe
lack of serious subjective side-effects, with the exception of
alopecia.
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